Drug Characteristics
  • Formulation

    Capsules: 150 mg

    Injection: 150 mg/ml (2 ml or 4 ml)        

  • Dose

    PCP treatment:

    Intravenous:

    600–900 mg IV every 6 or 8 hours and primaquine 15–30 mg orally once a day for 21 days

    Oral:

    300–450 mg orally four to three times a day and primaquine 15–30 mg orally once a day for 21 days

    Toxoplasmosis treatment :

    600 mg orally or IV four times a day for 6 weeks (in combination with pyrimethamine and folinic acid)

    Toxoplasmosis maintenance: 1200 mg daily in divided doses (in combination with pyrimethamine and folinic acid)        

  • Side Effects

    Diarrhoea (common), pseudomembranous colitis (less common), rash, hepatotoxicity, bone marrow suppression (rare)

    Methaemoglobinemia less likely if dose of primaquine 15 mg once a day is used        

  • Interactions

    Potentiates the effects of neuromuscular blocking agents

    Antagonism has been demonstrated between clindamycin and erythromycin

  • Renal

    Dose as in normal renal function

    Monitor closely in prolonged treatment courses        

  • Hepatic

    No data on dose reduction in hepatic dysfunction

    Monitor closely in prolonged treatment courses        

  • Pregnancy

    Compatible

  • Other Information

    Second-line agent for treatment of PCP (first line cotrimoxazole)

    Second-line agent for treatment of toxoplasmosis (first line sulfadiazine)